Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 15/20 | 0.54 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31676323 | 1.00 | SPPL2A (0.54) | SPPL2ASCDADAM17PPARDPPARA | |
| SCHEMBL31676094 | 0.92 | SPPL2A (0.54) | SPPL2APPARDPPARA | |
| SCHEMBL31676188 | 0.92 | SPPL2A (0.54) | SPPL2APPARDPPARA | |
| SCHEMBL31676409 | 0.92 | SPPL2A (0.64) | SPPL2ASCDADAM17PPARDPPARA | |
| SCHEMBL31675947 | 0.92 | SPPL2A (0.64) | SPPL2ASCDADAM17PPARDPPARA | |
| SCHEMBL31676406 | 0.91 | SPPL2A (0.52) | SPPL2ASCDPPARDPPARANPC1 | |
| SCHEMBL31676376 | 0.91 | SPPL2A (0.52) | SPPL2ASCDPPARDPPARANPC1 | |
| SCHEMBL31675939 | 0.90 | SPPL2A (0.66) | SPPL2ANPC1RAB9A | |
| SCHEMBL31676378 | 0.90 | SPPL2A (0.66) | SPPL2ANPC1RAB9A | |
| SCHEMBL31676115 | 0.86 | SPPL2A (0.64) | SPPL2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263416-A1 | SPPL2a INHIBITORS | INCYTE CORPORATION | 2025-08-21 | — | — | US | claimed |
| US-20250263416-A1 | SPPL2a INHIBITORS | INCYTE CORPORATION | 2025-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263416-A1 | SPPL2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | SPPL2A 1/4885SCD 2932/4885ADAM17 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.